eShowcase: Web Submission Data Manager Updated
New Version Extends Data Cleaning and Query Functions
New Version Extends Data Cleaning and Query Functions
Phase Forward (Waltham, MA) announces significant updates to its Web Submission Data Manager, WebSDM 2.6. WebSDM 2.6 integrates with the company's InForm Integrated Trial Management EDC product Version 4.6 and other database applications, and allows InForm 4.6 users to examine source records directly in the original context to understand data cleaning status and raise queries when needed at an earlier stage. This allows for detection of anomalies and trends for safety analysis.
WebSDM 2.6 also checks data for CDISC SDTM conformance, provides Web services API for automated data loading and improved integration with external data repositories such as Janus, and is validated for use on 64-bit platforms and Oracle Database 10g.
Phase Forward, (888) 703-1122, www.phaseforward.com
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
